TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07904767: Vision and Inflammation Study Testing Anti-acarid Therapeutics (VISTA-1X): A Phase 2, Open-Label, Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Adults With Blepharitis.

Sponsor: Aperta Biosciences, LLC · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$365,200

Rescue Site Savings

+$232,400

Unlock Full NCT07904767 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07904767 Rescue Dossier →